This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.
Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $10.01, marking a +1.11% move from the previous day.
Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZYNE) Outperforming Other Medical Stocks This Year?
Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $8.23, marking a -0.84% move from the previous day.
Will Zynerba Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals.
Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Will Zynerba Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals.
Has Zynerba Pharmaceuticals (ZYNE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ZYNE) Outperforming Other Medical Stocks This Year?
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.
Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock
by Zacks Equity Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Zynerba Pharma (ZYNE) Stock Soars on Positive Cannabis-Based Drug Results
by Madeleine Johnson
On Thursday, shares of clinical-stage specialty pharmaceutical company Zynerba Pharmaceuticals (ZYNE) are soaring, up nearly 54% in afternoon trading after it announced positive results in a mid-stage study of its cannabis-derived gel treatment.
Are Options Traders Betting on a Big Move in Zynerba Pharmaceuticals (ZYNE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Zynerba Pharmaceuticals (ZYNE) shares as it has huge implied volatility.
Play the Marijuana Rush as First Marijuana-Focused ETF Launches
by Arpita Dutt
The medical marijuana industry has been gaining a lot of importance and attracting interest from investors over the last few quarters with companies like GW Pharma (GWPH) making headlines.
Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14%
by Zacks Equity Research
Agile Therapeutics, Inc. (AGRX) moved big last session, as its shares rose almost 14% on the day.
Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report first-quarter fiscal 2017 results after the market closes on Mar 2.
DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?
by Zacks Equity Research
DexCom, Inc. (DXCM) is set to report fiscal fourth-quarter 2017 results on Feb 28.
Zynerba Pharmaceuticals (ZYNE) Shares March Higher, Can It Continue?
by Zacks Equity Research
Zynerba Pharmaceuticals, Inc. (ZYNE) has been on the move lately as the stock has risen by 19.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
Can Penumbra (PEN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.
Patterson Companies (PDCO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Patterson Companies Inc. (PDCO) is set to report fiscal third-quarter 2017 results on Feb 23, before the opening bell.
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
by Zacks Equity Research
Ireland-based medical device major Medtronic plc (MDT) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.
Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 9.5%
by Zacks Equity Research
Zynerba Pharmaceuticals, Inc. (ZYNE) moved big last session, as its shares jumped over 9% on the day.